Mayo Clinic IBD Biobank

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03756649

Enrollment

1000

Registered

2018-11-28

Start date

2018-11-01

Completion date

2065-12-01

Last updated

2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

IBD, Ulcerative colitis, Crohn's

Brief summary

Researchers are collecting and storing blood, stool, and urine samples and medical information to better understand Inflammatory Bowel Disease (IBD) to improve disease outcome.

Detailed description

Subjects will be sent a letter detailing the proposed biobank and soliciting enrollment. Following the informed consent process, subjects will provide a blood sample (50 ml), urine sample (50 ml), and stool. The blood and urine samples will either be collected at the one of the Mayo Clinic outpatient laboratories or by a mail-out kit. Subjects will be asked to complete a questionnaire and 24-hour food recall questionnaire (completed online).

Interventions

PROCEDUREBlood Draw

50 ml will be collected

PROCEDUREUrine Collection

50 ml will be collected

PROCEDUREStool Collection

Three 25 ml tubes will be collected

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of 18 and 85 at time of study enrollment. * The diagnosis of IBD will be based on the standard IBD criteria including biochemical and colonoscopy screening. * Women with inflammatory bowel disease of childbearing potential and pregnant women will be offered enrollment because there is no risk to an unborn child in this investigation. * Patients between the ages of 18 and 85 without history of IBD or colon cancer.

Exclusion criteria

* Patients with known liver disease. * Patients unable to provide informed consent. * Prisoners and institutionalized individuals. * Patients with a history of colorectal cancer.

Design outcomes

Primary

Measure	Time frame	Description
Study Participants	50 years	Total number of participants in the study

Secondary

Measure	Time frame	Description
Urine Collection	50 years	Total number of urine samples collected
Blood Collection	50 years	Total number of blood samples collected
Stool Collection	50 years	Total number of stool samples collected

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKonstantinos N. Lazaridis, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026